Japan health ministry panel approves expanded use of Chugai's COVID-19 antibody treatment - media

Chugai Pharmaceutical

04/11/2021 11:35

TOKYO, Nov 4 (Reuters) - A Japanese health ministry panel
approved the expanded use of Chugai Pharmaceutical Co's  4519.T 
COVID-19 antibody treatment to allow for preventative care,
local media reported on Thursday.
    Japanese regulators approved Chugai's antibody cocktail,
known as Ronapreve, as a treatment for COVID-19 in July.
    Chugai applied last month to allow the use of the drug as
prophylaxis for COVID-19 and as treatment of asymptomatic cases.
 urn:newsml:reuters.com:*:nT9N2QX00F

 (Reporting by Daniel Leussink; Editing by Toby Chopra)
 ((daniel.leussink@thomsonreuters.com; Twitter:
@danielleussink;))